RESEARCH ARTICLE

Open Access

Carbon monoxide down-regulates $\alpha_4\beta_1$ integrin-specific ligand binding and cell adhesion: a possible mechanism for cell mobilization

Alexandre Chigaev^{1,2,3*}, Yelena Smagley^{1,2,3} and Larry A Sklar^{1,2,3}

Abstract

Background: Carbon monoxide (CO), a byproduct of heme degradation, is attracting growing attention from the scientific community. At physiological concentrations, CO plays a role as a signal messenger that regulates a number of physiological processes. CO releasing molecules are under evaluation in preclinical models for the management of inflammation, sepsis, ischemia/reperfusion injury, and organ transplantation. Because of our discovery that nitric oxide signaling actively down-regulates integrin affinity and cell adhesion, and the similarity between nitric oxide and CO-dependent signaling, we studied the effects of CO on integrin signaling and cell adhesion.

Results: We used a cell permeable CO releasing molecule (CORM-2) to elevate intracellular CO, and a fluorescent Very Late Antigen-4 (VLA-4, $\alpha_4\beta_1$ -integrin)-specific ligand to evaluate the integrin state in real-time on live cells. We show that the binding of the ligand can be rapidly down-modulated in resting cells and after inside-out activation through several G_{i1} -coupled receptors. Moreover, cell treatment with hemin, a natural source of CO, resulted in comparable VLA-4 ligand dissociation. Inhibition of VLA-4 ligand binding by CO had a dramatic effect on cell-cell interaction in a VLA-4/VCAM-1-dependent cell adhesion system.

Conclusions: We conclude that the CO signaling pathway can rapidly down-modulate binding of the VLA-4 -specific ligand. We propose that CO-regulated integrin deactivation provides a basis for modulation of immune cell adhesion as well as rapid cell mobilization, for example as shown for splenic monocytes in response to surgically induced ischemia of the myocardium.

Keywords: Carbon monoxide, Hemin, Integrin, Affinity, Conformation, Cell adhesion

Background

Since the discovery that endogenous CO can serve as a neurotransmitter [1] and that it exhibits anti-inflammatory properties [2] the number of papers devoted to CO signaling and therapeutic applications has increased every year [3-6]. Since the roles of the two major gaseous messengers, CO and nitric oxide (NO) are somewhat similar [7], and our recent discovery of rapid effects of NO on integrin ligand binding affinity and cell adhesion [8], we studied the effects of CO on integrin regulation.

Integrins are cell adhesion receptors that are capable of modulating rapid adhesion and de-adhesion events, without a change in the number of molecules expressed [9]. Ligand interactions with integrins represent the molecular basis of integrin-dependent cell adhesion. Integrin-dependent cell adhesion is controlled by the conformational state of the molecule through ligand binding affinity and extension that are regulated by a number of signaling pathways initiated by other cellular receptors. This so-called inside-out signaling serves as the basis for rapid leukocyte arrest on endothelium, cell migration and chemotaxis, mobilization, trafficking, and interaction of immune cells [10,11]. $\alpha_4\beta_1$ -integrin (CD49d/CD29, Very Late Antigen-4, VLA-4) is expressed on leukocytes, dendritic cells, hematopoietic progenitors, and stem cells, as well as cancer cells of differing origin [12,13]. The goal of the current study was to examine the effects

* Correspondence: achigaev@salud.unm.edu

¹Department of Pathology and University of New Mexico Cancer Center, Albuquerque, NM 87131, USA

²University of New Mexico Center for Molecular Discovery, Albuquerque, NM 87131, USA

Full list of author information is available at the end of the article

of the CO signaling pathway on VLA-4 conformational regulation.

To date, a limited number of studies have been dedicated to the effects of CO on leukocyte integrin-dependent adhesion. The down-regulation of leukocyte extravasation and leukocyte endothelial cell interaction, as well as the effects on integrin or integrin ligand expression have been reported [14-19]. To the best of our knowledge, this report represents the first time that the effects of CO and a natural source of CO, hemin, on integrin ligand binding have been studied on live cells in real-time under inside-out signaling conditions. Our findings provide a molecular mechanism for inhibition of integrin-dependent leukocyte adhesion and the beneficial effects of CO-associated therapies in a number of pathologies [4].

Results

Carbon monoxide signaling and pathway modulation

Endogenous CO is produced inside cells as a product of enzymatic degradation of heme catalyzed by the enzyme heme oxygenase (HO) that consists of two isoforms: HO-1 is inducible, and HO-2 is a constitutive form [20]. HO is localized in the cytosol and mitochondria [21]. The major source of heme for CO production is hemoglobin, and other hemoproteins (Figure 1). CO has been shown to stimulate soluble guanylyl cyclase, stimulate vasodilatation, block cell proliferation, participate in neural transmission, and inhibit platelet aggregation (see [20] and references therein). CO targets several heme-containing proteins and soluble guanylyl cyclase (sGC) was recognized as the first and the most studied "CO receptor". Multiple physiological effects including vasodilatation and platelet aggregation are attributed to the cGMP/PKG-dependent arm of the CO signaling pathway. Other signaling molecules such as p38 MAPK, ERK1/2, and JNK can be regulated through other "CO sensors" [20,22].

To study the effects of CO/cGMP signaling in leukocytes, we selected several small molecules that specifically target this pathway (Figure 1). Tricarbonyldichlororuthenium (II) dimer, Carbon Monoxide-Releasing Molecule 2 (CORM-2), can be described as a complex of a transition metal ruthenium with carbon monoxide [23]. It spontaneously releases CO and is used as a carbon monoxide donor. It exerts a vasodilatory effect in isolated blood vessels, [24]. CORM-2 *in vivo* is shown to diminish adhesion and accumulation of PMNs in injured mice [25,26]. Hemin is a heme substrate analog and an inducer of HO-1 expression [19]. The conversion of one molecule of heme into biliverdin results in the release of one molecule of CO. The HO enzyme that generates CO from hemin is expressed in our model system, and hemin addition has been shown to decrease pro-inflammatory cytokine levels in U937 cells [27]. BAY 41-2272 is an activator of soluble guanylyl cyclase, which was shown to stimulate cGMP

Figure 1 CO signaling cascade and small molecules used to modulate this pathway. Endogenous carbon monoxide is generated by heme oxygenase (HO). In cells CO reacts with hemoproteins. One of the CO receptors is the guanylyl cyclase (GC) that produces the intracellular messenger cyclic GMP (cGMP). cGMP interacts with the cGMP-dependent protein kinase (PKG), which phosphorylates multiple substrates, and participates in signal propagation. The carbon monoxide donor provides an exogenous source of CO. The natural HO substrate hemin increases CO production because conversion of heme into biliverdin represents the rate-limiting step in heme degradation [5]. The activator of soluble guanylyl cyclase binds to GC, and induces enzyme activation in the absence of CO. The cell permeable analog of cGMP diffuses across the plasma membrane, and thus, activates cGMP-dependent signaling.

production [28]. N²,2'-O-dibutyrylguanosine 3',5'-cyclic monophosphate is a cell permeable cGMP analog that activates protein kinase G [29]. All these molecules are shown to stimulate different steps of the signaling pathway (Figure 1), and therefore, are used to mimic CO-dependent signaling.

The CO donor induces a rapid decrease in the binding of the VLA-4 specific ligand

The VLA-4-specific ligand (LDV-FITC) is a small fluorescent probe based on the published structure of BIO1211, a CD49d/CD29 specific antagonist [30-32]. The molecule contains the Leu-Asp-Val (LDV) ligand binding motif from the alternatively spliced connecting segment-1 (CS-1) peptide of fibronectin. The major advantage of this probe is that it can be used to detect VLA-4 conformational changes on live cells in real-time in response to cell signaling

[8,33,34]. The binding affinity detected using LDV-FITC varies in parallel with VCAM-1, the major natural VLA-4 ligand [35]. VCAM-1 contains the Ile-Asp-Ser (IDS) motif homologous to LDV, and VLA-4 interaction with VCAM-1 can be blocked by LDV-containing molecules [35-37]. To determine the effect of the CO donor on resting cells, samples were first treated with 25 nM LDV-FITC (Figure 2A). This concentration is about 2 fold higher than the dissociation constant for LDV-FITC binding to U937 cells without activation ($K_d \sim 12$ nM, [30]). Therefore, 70–80% of low affinity sites are occupied. Next, the addition of CORM-2 resulted in the dose-dependent dissociation of LDV-FITC that reached a steady-state 5–6 min after addition. Finally, an excess of unlabeled competitor (LDV) was added to determine the non-specific binding of the probe (Figure 2A). This induced rapid LDV-FITC dissociation with a rate (k_{off}) similar to the rate reported for resting cells [35]. To determine the EC₅₀ for the effect of CORM-2 on LDV-FITC binding, the span of the single exponential fits for the dissociation curves after LDV addition was plotted *versus* the logarithm of CORM-2 concentration (Figure 2B).

Next, to study the effect of the CO donor on cells activated through the “inside-out” signaling pathway, we used U937 cells stably transfected with the non-desensitizing mutant of the formyl peptide receptor (FPR). Because serine and threonine in the C-terminal tail of GPCRs phosphorylated by G protein-coupled receptor kinases upon ligation are critical for the binding of arrestin and receptor desensitization [38,39], we used a mutant FPR lacking all serines and threonines (FPR Δ ST) [40]. After ligation of this receptor with a high affinity ligand N-formyl-Met-Leu-Phe-Phe FPR signaling persists and the high affinity of the VLA-4 ligand binding pocket is maintained for thousands of seconds [8,34].

To observe real-time inside-out VLA-4 activation, cells were first treated with 4 nM LDV-FITC (Figure 2C). This concentration is below the dissociation constant (K_d) for its binding to resting VLA-4 (low affinity state, $K_d \sim 12$ nM), and above the K_d for physiologically activated VLA-4 (high affinity state, $K_d \sim 1$ -2 nM) [30]. Thus, the transition from the low affinity to the high affinity receptor state led to increased binding of the probe (from ~25% to ~70-80% of receptor occupancy) [41]. Therefore, the binding of additional LDV-FITC molecules is detected as a rapid increase in the cell fluorescence. Because the laser of the flow cytometer excites only a small volume of solution around the cell, the detection of probe binding is possible in a homogeneous (no-wash) format [42,43]. Next, the addition of CORM-2 resulted in the dose-dependent dissociation of LDV-FITC. Excess unlabeled competitor (LDV) was used to determine the non-specific binding of the probe (Figure 2C). The LDV-FITC dissociation rate (k_{off}) was

slower but similar to the rate reported for cells activated through inside-out GPCR signaling [30,35]. The EC₅₀ for the effect of CORM-2 on activated cells was somewhat higher than for resting cells (Figure 2D).

To establish whether the effect of CORM-2 was mediated by CO, we conducted two control experiments (Figure 2E, F). First, cells were treated with RuCl₃ at a concentration equal to the highest concentration used of CORM-2 (150 μ M). RuCl₃ is a product of CORM-2 degradation, and therefore, it was used as a negative control in CORM-2 experiments [44-47]. No statistically significant effects of RuCl₃ on LDV-FITC binding or dissociation were detected (Figure 2E).

As a second control we took advantage of the limited stability of CORM molecules [48]. First, a stock solution of CORM-2 was prepared and incubated at room temperature for 48 hours. The effect of this old solution was compared to a fresh equimolar CORM-2 solution prepared prior to the experiment (Figure 2F). The freshly prepared solution induced significantly higher dissociation. Thus, because gaseous CO is released into the air over time, the difference between fresh and old CORM-2 solution may be attributed to the lower concentration of CO in the old solution. Based on the two controls we concluded that the effect of CORM-2 is attributed to CO released by the CO donor.

Effect of the CO donor on the binding of VLA-4 specific ligand during inside-out activation through CXCR4 and CXCR2

Cell activation through wild type GPCRs induces a rapid and reversible VLA-4 affinity change due to receptor desensitization [30]. Therefore, in CXCR4 and CXCR2 experiments, the CO donor was added two minutes prior to the addition of GPCR ligands (Figure 3). The treatment of cells stably transfected with wild type CXCR4 or CXCR2 significantly decreased the amplitude of the ligand-induced LDV-FITC response. Thus, similar to a non-desensitizing mutant of FPR the effect of the CO donor can be observed for signaling through other G-protein coupled receptors. This result is similar to the previously reported effect of NO on GPCR-induced VLA-4 activation [8].

Hemin, a natural substrate of HO and a natural source of CO, rapidly decreases binding of the VLA-4 specific ligand Heme oxygenase is expressed in U937 cells [49-51], and exogenous hemin can be used to modulate cell signaling in this cell line [27,52]. To study the effect of hemin on LDV-FITC binding on resting and activated cells, experiments were conducted in a manner similar to the CO donor experiments (Figure 2). Resting U937 cells were treated with 25 nM LDV-FITC (Figure 4A). Next, appropriate concentrations of hemin were added. We observed a slow dose-dependent decrease in the LDV-FITC signal.

Figure 2 Effect of CO donor on binding and dissociation of the LDV-FITC probe on resting and activated cells. LDV-FITC binding and dissociation on U937 cells stably transfected with the non-desensitizing mutant FPR Δ ST plotted as LDV-FITC fluorescence versus time. The data were normalized to the level of the non-specific signal determined by addition of excess unlabeled competitor (LDV), and therefore, no autofluorescence can be seen. **A.** The experiment involved sequential additions of the LDV-FITC, and different concentrations of CORM-2 or vehicle. The non-specific binding of the probe was determined using LDV. Ligand dissociation rates (k_{off}) were determined by fitting the dissociation part of the curves to the single exponential equation. **B.** The span of the single exponential fits for the dissociation curves (from A after LDV addition) plotted versus logarithm of CORM-2 concentration. Means $\pm$ SEM of two independent determinations are shown. The sigmoidal dose-response (Hill slope = 1) was fit using GraphPad Prism. **C.** The sequential addition of the LDV-FITC, the high affinity FPR ligand (fMLFF), CORM-2 or vehicle, and LDV. LDV-FITC k_{off} s were determined as described for A. The level of LDV-FITC binding corresponding to resting cells is indicated by the dashed line. **D.** The span of single exponential fits for the curves (from panel C) plotted versus logarithm of CORM-2 concentration. Means $\pm$ SEM of two independent determinations are shown. The dose-response was fit analogously to B. **E.** The experiment involved addition of the LDV-FITC, RuCl $_3$ or vehicle. **F.** The sequential addition of the LDV-FITC, and CORM-2. The "old" CORM-2 was prepared by incubating the solution for 48 hours at room temperature. The non-specific binding of the LDV-FITC probe was determined using LDV. For panels A, C, E, and F, a representative experiment of two independent experiments is shown.

Figure 3 Effect of CO donor pretreatment on binding and dissociation of the LDV-FITC probe in cells stably transfected with CXCR4 and CXCR2, then treated with different G α i-coupled receptor ligands. **A.** The experiment involved sequential addition of CORM-2 (75–150 μ M, CO donor) or DMSO (control), the fluorescent LDV-FITC probe (4 nM), CXCL12/SDF-1 (12 nM), and excess unlabeled LDV competitor (1 μ M). Rapid and reversible binding of the probe reflects the VLA-4 affinity change. **B.** The experiment involved sequential addition of CORM-2 (75 μ M, CO donor) or DMSO (control), the fluorescent LDV-FITC probe (4 nM), CXCL8/IL-8 (20 nM), and excess unlabeled LDV competitor (1 μ M). A representative experiment of two independent experiments is shown.

Finally, to determine the non-specific binding of the LDV-FITC probe, excess unlabeled competitor was added 10–12 min later. As in the case of the CO donor, the ligand dissociation rate (k_{off}) was similar to the rate reported for resting cells. To determine the EC₅₀ for the effect of hemin on LDV-FITC binding, the span of single exponential fits for the dissociation curves after LDV addition was plotted *versus* the logarithm of hemin concentration (Figure 4B). The effect of hemin was similar to the effect of the CO donor on resting cells.

The effect of hemin on “inside-out” activated cells (Figure 4C) has been studied in a manner analogous to the CO donor experiments (Figure 2C). Cells were treated with LDV-FITC, FPR ligand for cell activation, appropriate concentrations of hemin, and the unlabeled LDV competitor (Figure 4C). Analogous to the CO donor results, the ligand dissociation rate (k_{off}) was similar to the rate reported for activated cells, and the EC₅₀ for the effect of hemin on activated cells was comparable to the EC₅₀ for resting cells (Figure 4D). Thus, the natural source of CO, hemin, exhibited activity that was analogous to that of the artificial CO donor. Both compounds induced rapid dissociation of the VLA-4 specific ligand.

Carbon monoxide donor produces a small effect on VLA-4 subunit surface expression

To study the effect of CO signaling on VLA-4 surface expression, cells were treated with the CO donor or vehicle for 30 min at 37°C. Next, cells were stained with primary labeled antibody against α 4- and β 1-integrin subunits (Figure 5). Analysis of antibody binding revealed a decrease in the surface expression of both integrin

subunits that varied from 10% to 26% in multiple experiments. Given the small sample to sample variation this difference was statistically significant (Figure 5B). However, this difference in the expression of VLA-4 subunits detected after 30 min of CO donor treatment cannot account for rapid and dramatic decrease in the VLA-4-specific ligand binding that has been detected after CO donor addition (Figure 2B,C).

Carbon monoxide donor diminishes VLA-4 /VCAM-1-dependent cell adhesion

Next, to study the implications of the CO signaling pathway on integrin-dependent cell adhesion, we utilized a VLA-4/VCAM-1-specific real-time cell aggregation assay [35]. The specificity of cell aggregation in this model system was tested using anti- α 4-integrin blocking mAb as well as unlabeled LDV that completely blocked cell aggregation [35,53]. Prior to mixing, U937 cells constitutively expressing VLA-4 were labeled with green fluorescent dye, and B78H1 cells stably transfected with human VCAM-1 were stained with red fluorescent dye (Figure 6A). The cell aggregates were detected as red and green co-fluorescent events in real-time. Cells were mixed and the baseline aggregation data were collected for the first three minutes. Next, the tube was removed and an aliquot of stock solution of carbon monoxide donor CORM-2 in DMSO or equal volume of vehicle (DMSO) were added. The tube was rapidly replaced and data acquisition was reestablished. The data were collected for up to 30 min (Figure 6B).

The CO donor treatment was sufficient to fully reverse cell aggregation (Figure 6B). During the first three minutes of the experiment no significant difference between the

Figure 4 Effect of hemin on binding and dissociation of the LDV-FITC probe on resting and activated U937 cells. LDV-FITC probe binding and dissociation on U937 cells plotted as LDV-FITC fluorescence versus time. The data were normalized to the level of the non-specific signal determined by the addition of excess unlabeled competitor (LDV 2 μM), and therefore, no cell autofluorescence can be seen. **A.** The experiment involved sequential addition of the fluorescent LDV-FITC probe (25 nM), and different concentrations of hemin (6–100 μM) or DMSO (vehicle). The non-specific binding of the LDV-FITC probe was determined using excess unlabeled competitor (LDV). Ligand dissociation rates (k_{off}) were determined by fitting the dissociation part of the curves (after LDV addition) to the single exponential equation. The range of k_{off} is shown. **B.** The span of the single exponential fits for the dissociation curves (from panel A after LDV addition) plotted versus logarithm of hemin concentration. Means $\pm$ SEM of two independent determinations are shown ($n = 2$). The sigmoidal dose–response fit (Hill slope = 1) was obtained using GraphPad Prism software. **C.** The experiment was conducted using U937 cells stably transfected with the FPR Δ ST receptor, and involved sequential addition of the fluorescent LDV-FITC probe (4 nM), the high affinity FPR ligand N-formyl-Met-Leu-Phe-Phe (100 nM), hemin (1.5–100 μM) or DMSO (control), and LDV (2 μM). LDV-FITC dissociation rates (k_{off}) were determined as described for panel A. **D.** The span of the single exponential fits for the dissociation curves (from panel C, after LDV addition) plotted versus logarithm of hemin concentration. Means $\pm$ SEM of two independent determinations are shown ($n = 2$). The sigmoidal dose–response fit was obtained analogously to panel B.

two samples was detected. After the addition of CORM-2, cells continued to aggregate for ~2 minutes, and then aggregate accumulation stopped and disaggregation occurred. The sample treated with vehicle exhibited a long-term accumulation of cell aggregates that reached 30–40% by the end of the experiment (Figure 6B). The difference between samples treated with the CO donor and untreated samples was statistically significant (Figure 6C).

Thus, the CO donor added to the cell suspension in real-time prevented VLA-4/VCAM-1-dependent aggregation.

The carbon monoxide donor decreases the binding affinity of the VLA-4 specific ligand

Next, to quantify the effect of CO on VLA-4 specific ligand binding affinity, we evaluated the binding of unlabeled LDV ligand using a Ligand Induced Binding Site (LIBS) antibody.

Figure 5 Effect of CO donor on surface expression of VLA-4 (CD49d/CD29 heterodimer). U937 cells were treated with vehicle (DMSO, control), and CO donor (150 μ M CORM-2) for 30 min at 37°C. Next, cells were placed on ice and stained with primary labeled anti-CD29 and anti-CD49d antibodies, or the isotype control. **A.** Histograms of anti-CD29 and anti-CD49d antibodies are shown in black, and the isotype control is grey. **B.** Bar graphs of mean channel fluorescence (MCF) $\pm$ SEM (n =5) for unstained cells (autofluorescence), nonspecific binding to cells (isotype control), cells treated with vehicle (DMSO), and cells treated with CORM-2 are shown (10,000 gated events for each sample were collected). One representative experiment of three experiments is shown. * indicates means are significantly different (P <0.05) as estimated by the unpaired t test analysis using GraphPad Prism software.

Binding of ligands to integrins induces a series of conformational changes that result in the exposure of previously hidden epitopes. A LIBS antibody can recognize these

epitopes. This mAb feature can be used to detect ligand occupied integrin receptors. The parental ligand molecule (BIO1211) [32], and the LDV ligand are known to induce

Figure 6 Effect of CO donor on cell adhesion between U937 cells and VCAM-1-transfected B78H1 cells. **A.** Dot plot of flow cytometric analysis of cell aggregation. Cells were labeled with red and green fluorescent dyes. Next, cells were mixed at 0 time point. During data acquisition samples were maintained at 37°C, and continuously stirred with a magnetic stir bar. An increase in the number of aggregates was detected as green and red co-fluorescent particles indicated by the circular gate. **B.** Real-time cell aggregation plotted as % aggregates (Agg. %) versus time. The data were normalized to the non-specific aggregation determined as cell aggregation in the presence of excess unlabeled competitor (1 μ M LDV). A representative experiment out of two experiments is shown. **C.** Statistical significance of the CO donor effect on cell aggregation. The aggregate percentage data from the last 5 min of the experiments (B) are compared using the unpaired t test. Means are significantly different ($P < 0.05$).

LIBS epitopes [41,54]. To determine the ligand binding affinity (K_d) for the unlabeled molecule, cells are incubated with increasing concentrations of the ligand in the presence of a constant concentration of the primary labeled LIBS mAb [33]. Because flow cytometers have the ability to discriminate between free and bound fluorescent molecules in a homogeneous assay [42], the concentration of the unlabeled ligand-receptor complex is proportional to the fluorescence of the fluorophores associated with the mAbs [54]. The major advantage of this approach, compared with direct binding of a fluorescent ligand, is that there is no limit to the ligand concentration. Because the LDV ligand is unlabeled, no non-specific fluorescence increase with ligand concentration is observed, and virtually no non-specific antibody binding is detected [33,41,54]. This assay allows the detection of integrin affinity changes that differ by several orders of magnitude [55].

Cells were incubated in the presence of increasing concentrations of unlabeled LDV and phycoerythrin-labeled anti-CD29 LIBS antibody (HUTS-21) in the presence or absence of the CO donor. As shown

previously, the EC_{50} for mAb binding is similar to the ligand dissociation constant (K_d) determined using other methods [54]. We observed that the EC_{50} s for LIBS antibody binding for CORM-2 treated samples were larger than for the vehicle treated controls by ~2 fold for resting cells, and ~3 fold for FPR activated cells (Figure 6). This indicated a decrease in the ligand binding affinity. Also, the fact that the maximal binding of LIBS antibody for CORM-2 treated samples was ~5-10% lower was suggested by the change in VLA-4 receptor surface expression (CD49d/CD29 complex) as detected using anti-CD49d and anti-CD29 antibodies (Figure 5).

To evaluate the effects of the CO donor on the affinity of the VLA-4 specific ligand we compared data obtained using fluorescent LDV-FITC (Figures 2A,C and 4A,C) with LDV binding detected using LIBS (Figure 7). Notice that the two highest concentrations of the CO donor or hemin induced very similar effects (see Figures 2A and 4A). The decrease in LDV-FITC binding on resting cells saturated at ~30% for both compounds. Quantitatively, in order to observe a decrease from 68% occupancy for

Figure 7 Effect of CO donor on binding of primary labeled LIBS (HUTS-21) to U937 cells in the presence of different concentrations of LDV. Mean fluorescence intensity plotted versus concentration of unlabeled LDV. **A.** U937 cells were treated with vehicle (DMSO, control), and CO donor (150 μ M CORM-2) for 30 min at 37°C. Next, cells were incubated with the indicated concentration of LDV in the presence of excess HUTS-21 mAbs, washed, and fluorescence was measured. **B.** U937 cells stably transfected with the non-desensitizing FPR mutant were treated with vehicle (DMSO, control), and CO donor (150 μ M CORM-2) for 30 min at 37°C in the presence of 100 nM fMLFF for cell activation. Next, mAb binding was performed in a manner analogous to A. The non-specific binding of HUTS-21, detected in the absence of LDV ligand, was subtracted from the data. Means $\pm$ SEM of three independent determinations are shown. The data were fitted using the sigmoidal dose-response equation with GraphPad Prism software. One representative experiment out of three independent experiments is shown.

the binding of the LDV-FITC ligand on resting cells (the initial binding occupancy as calculated based on resting VLA-4 K_d ~12 nM [30], and LDV-FITC concentration 25 nM) to ~30%, a ~4.8 fold increase in the K_d would be required (at K_d ~58 nM, ligand concentration 25 nM, receptor occupancy ~30% as derived from the one-site hyperbolic binding equation).

For FPR activated cells, a decrease from ~80% initial occupancy (K_d ~1 nM, and LDV-FITC concentration 4 nM), down to ~25% occupancy, requires a ~12 fold increase in the K_d (at K_d ~12 nM, ligand concentration 4 nM). This suggests that the effect of CO is more

significant in the case of integrins activated through inside-out signaling. It is worth noting that K_d ~12 nM corresponds to the K_d detected on resting cells, and the real-time decrease in LDV-FITC binding after CORM-2 addition reached a plateau at a level that was close to the level corresponding to the resting cell (before FPR activation, Figure 2C). This observation additionally supports our calculations.

The effect of the CO donor on the ligand affinity change detected using the LIBS antibody was smaller. We detected only two to three fold differences in the EC50s (Figure 7). The EC50 for fMLFF activated cells (Figure 7B) was higher than the K_d estimated using dissociation rate analysis [30,35,56]. This discrepancy may be attributed to desensitization of FPR signaling after long-term incubation in the presence antibodies. This data additionally emphasizes the importance of rapid real-time approaches for studying cell signaling [33].

The activator of soluble guanylyl cyclase and the cell permeable cGMP analog decrease the binding affinity of the VLA-4 specific ligand

The effects of BAY 41-2272, an activator of soluble guanylyl cyclase and dibutyrylguanosine 3',5'-cyclic monophosphate, a cell permeable cGMP analog, (Figure 1) were studied previously as part of our study of nitric oxide signaling and VLA-4 regulation [8]. We found that BAY 41-2272 induced a rapid dose-dependent down-regulation of LDV-FITC binding after activation through CXCR4, CXCR2, and the non-desensitizing mutant of FPR. Cell treatment with BAY 41-2272 exhibited faster dissociation rates (k_{off}) indicating a decrease of the affinity of the VLA-4 specific ligand. DbcGMP also induced rapid and dose dependent down-regulation of LDV-FITC binding [8]. Given the similarity between NO and CO signaling and their functional roles, both gases stimulate guanylyl cyclase [7,57]. These data support the role of the CO signaling pathway in regulating VLA-4 conformation and cell adhesion.

Discussion

Do cyclic nucleotides act as universal anti-adhesive integrin regulators?

During the last few years we have described two signaling pathways that can rapidly down-regulate the binding of the VLA-4 specific ligand and cell adhesion: the G α s-coupled receptor signaling pathway and the NO/cGMP signaling pathway [8,34]. CO-mediated VLA-4 inactivation is described in this report. One common feature of these pathways is the modulation of nucleotide cyclases leading to up-regulation of cyclic nucleotide (cAMP and cGMP) levels. Similar downstream signaling mechanisms, related to nucleotide-dependent kinases [58] and other effectors, suggest the need for further evaluation of the

role of cyclic nucleotide-dependent pathways in integrin-dependent cell de-adhesion. The literature reveals that these pathways can participate in cell mobilization, demargination, detachment, or deployment, all of which can be linked to a decrease of $\alpha 4$ -integrin-dependent cell adhesion.

For G α s-coupled GPCRs, such as the $\beta 2$ -adrenergic receptor or the H 2 -histamine receptor, specific ligand agonists and antagonists, as well as an adenylyl cyclase activator and a cell permeable cAMP analog were able to rapidly modulate the affinity of the integrin and cell adhesion after SDF-1/CXCR4 or FPR mediated activation [34]. This signaling pathway may participate in demarginating nonclassical monocytes [59] and CD8 $^{+}$ effector T-cells [60], triggering rapid detachment of PBMCs attached to the endothelium [61], mobilizing natural killer cells [62-64], and playing a role in $\beta 2$ -adrenergic receptor and cAMP-induced leukocytosis [65-67]. However, further studies are needed to dissect the interplay between cytokines and this signaling pathway [68]. Rapid mobilization of hematopoietic stem progenitor cells (HSPCs) mediated specifically through VLA-4 adhesion and SDF-1/CXCR4-dependent signaling [55,69-75] was induced by $\beta 2$ -adrenergic receptor agonists, and can be blocked by a specific antagonist in mice [76]. We envision that $\beta 2$ -adrenergic receptor/cAMP-dependent VLA-4 deactivation [34] provides one of the molecular mechanisms for regulating stem progenitor cell egress from the bone marrow [77,78]. Another mechanism can be related to NO signaling.

Our discovery that the NO/cGMP signaling pathway rapidly deactivates high affinity VLA-4 pre-activated by SDF-1/CXCR4 signaling and other G α i-coupled GPCRs [8] provides a plausible explanation for the observation that links NO-mediated signaling and nitric oxide synthase with stem and progenitor cell trafficking and mobilization. Mice deficient in endothelial nitric oxide synthase (NOS3 or eNOS) exhibited impaired mobilization of endothelial progenitor cells (EPC) from the bone marrow. The expression of CD29 (VLA-4 $\beta 1$ -subunit) and CXCR4 remained unaltered in NOS3 $^{-/-}$ mice, but neither the conformation nor affinity state of the integrin was tested [79]. Bone marrow stromal and vascular cells express large quantities of NOS. These cells are envisioned to be a major source of NO. Both stromal and vascular cells express VEGF-receptor-2 (Flk-1), and VEGF is one of the major factors mobilizing endothelial progenitors from bone marrow [80,81]. VEGF has been shown to activate NO release through AKT-dependent phosphorylation of eNOS [80,82-85]. Thus, NO-triggered deactivation of VLA-4 could complement VEGF-induced stem cell mobilization (see Figure 3 in [82]). It is possible that the effect of NO is specific to CD34 $^{+}$ Flk-1 $^{+}$ EPCs. Under NO-deficient conditions EPCs failed to be mobilized into the peripheral

blood. The c-kit $^{+}$ Lin $^{-}$ HSPCs were not affected by nitric oxide [86]. Thus, existing data support specific role of cyclic nucleotide-related signaling as a regulator of cell mobilization, demargination, or detachment under G α s-coupled GPCRs or NO signalling.

CO in macrophages

The effect of CO is typically attributed to the enzymatic catabolism of heme, and the majority of CO (up to ~70%) is produced from hemoglobin originating from the breakdown of erythrocytes [20]. Splenic red-pulp macrophages are responsible for the removal of senescent red blood cells from the circulation, during filtration of blood through the spleen [87]. These macrophages express heme oxygenase-1 (HO-1) that metabolizes heme and produces iron, biliverdin, and carbon monoxide [4]. HO-1 is essential for splenic macrophage function, since in HO-1 $^{-/-}$ mice macrophages are destroyed through exposure to unmetabolized heme [88]. At the same time, the spleen is reported to serve as a reservoir for resident macrophages that can be rapidly deployed in the peripheral blood in response to surgically induced ischemia of the myocardium [89]. The data presented in this report suggest a possible mechanism for the deployment phenomenon.

Erythrocyte damage can be induced by a number of factors that include ischemia and inflammation. This may lead to the increased clearance of red blood cells [90]. As a result, increased phagocytosis by splenic macrophages can lead to rapid up-regulation of heme catabolism and intra-macrophage CO production. This is expected to down-modulate integrin affinity and cell adhesion within the phagocyte. It is also possible that CO can diffuse from the phagocyte and act in a paracrine manner on macrophages residing in close proximity. The loss of cell adhesion could result in macrophages entering the circulation through the efferent splenic vein. This scenario seems plausible specifically because of the role of $\alpha 4$ -integrins in splenic homing [87,91].

Another possible implication of the anti-adhesive impact of CO signaling is in ischemia-reperfusion injury and transplantation [4]. Adhesion molecules and specifically $\beta 1$ - and $\beta 2$ - integrins are envisioned as feasible targets for preventing reperfusion injury through blocking leukocyte extravasation and recruitment [92-94]. The successful application of CO for organ transplant could be accompanied by reduced recruitment of leukocytes, macrophages, and T-cells to the graft [95], and the overall anti-inflammatory effect of CO could also be related to blocking integrin-dependent immune cell adhesion [4]. Thus, it seems that the enzymatic catabolism of heme in macrophages and resulting intra-macrophage CO production are critical for rapid down-regulation of integrin-mediated cell adhesion, rapid re-entry of adherent cells into circulation, or blocking of leukocyte extravasation

and recruitment to the sites of inflammation. We propose that therapeutic modulation of this pathway can serve as a viable alternative to a direct modulation of cell adhesion using integrin antagonists for example.

CO, integrins, and immune response

The release and accumulation of heme in peripheral blood can result from hemolysis that occurs as a consequence of bacterial infection [96]. Free heme plays a crucial role in the pathogenesis of sepsis [97]. Since VLA-4 and VLA-5 are known to regulate phagosome maturation and microorganism clearance in macrophages [98], the pathogen-induced damage of erythrocytes, which decreases integrin binding through activation of the CO/cGMP pathway, should promote pathogen survival. In particular, the lipopolysaccharide-binding pattern recognition molecule mindin (spondin-2) specifically interacts with CD49d/CD29 [99] though the LEV (Leu-Glu-Val) integrin-binding motif [100] homologous to the LDV (Leu-Asp-Val) binding motif in fibronectin [101]. Mindin is essential for microorganism clearance because mindin-deficient macrophages show defective phagocytosis [102]. Therefore, one would expect that the binding of mindin to VLA-4 will be regulated by CO in a manner similar to that of the LDV probe, described in the current report. Thus, a release of large amount of free heme and a subsequent CO production in macrophages will provide a protection of pathogens against microorganism clearance. However, no significant effect of exogenous heme administration on the number of bacterial colony-forming units in the blood and peritoneum of mice subjected to a nonlethal polymicrobial infection were found, and the ability of heme to precipitate sepsis was not directly related to the pathogen load [97]. Nevertheless, because hemolysis can be caused by pore-forming toxins produced by many blood-borne pathogens [103], the amount of free heme should be directly related to the bacterial load. The pore forming toxins are known to contribute to the evasion of host defence by the inhibition of innate immune responses in macrophages [104]. Thus, a number of immunological phenomena related to pathogen-induced hemolysis can be related to the regulation of VLA-4 integrin-mediated binding of pattern recognition molecules, phagosome maturation and microorganism clearance in macrophages. The ability to release free heme, induce production of large amount of CO, and thus block integrin-dependent cell adhesion could be one of the previously unrecognised immune evasion mechanisms employed by haemolytic pathogens.

Conclusions

We conclude that CO from an artificial donor or a natural CO source (hemin) down-modulated binding of the VLA-4 integrin-specific ligand at rest and after inside-

out activation through several G α_i -coupled receptors activation. This results in a rapid down-modulation of integrin-dependent cell adhesion. We propose that CO-triggered integrin deactivation represents a novel mechanism that provides a molecular basis for several phenomena related to the mobilization of different cell subsets, and the evasion of the immune response.

Methods

Materials

The VLA-4-specific ligand 4-((N'-2-methylphenyl)ureido)-phenylacetyl-L-leucyl-L-aspartyl-L-valyl-L-prolyl-L-alanyl-L-alanyl-L-lysine (LDV) and its FITC-conjugated analog (LDV-FITC probe) [30,33] were synthesized at Commonwealth Biotechnologies. Mouse anti-human CD29/integrin β_1 chain, clone MAR4 (PE), mouse anti-human CD49d/integrin α_4 chain, clone 9F10 (PE), and isotype control (mouse IgG1 κ , PE) clone MOPC-21 were purchased from BD Biosciences and used according to the instructions of the manufacturer. Human recombinant CXCL12/SDF-1 α and recombinant human CXCL8/IL-8 were obtained from R&D Systems, Inc. All other reagents were from Sigma-Aldrich. Stock solutions were prepared in DMSO, at concentrations ~1000-fold higher than the final concentration. Usually, 1 μ l of stock solution was added to 1 ml of cell suspension, yielding a final 0.1% DMSO concentration. Control samples were treated with an equal amount of pure DMSO (vehicle).

Cell lines and transfectant construct

The human histiocytic lymphoma cell line U937 and mouse melanoma cell line B78H1 were purchased from ATCC. Wild type CXCR4 (CD184) receptor-stably transfected U937 cells, wild type CXCR2 (IL8RB)-stably transfected U937 cells, and the non-desensitizing FPR Δ ST mutant in U937 cells were prepared as described [105], and were a gift of Dr. Eric Prossnitz (University of New Mexico). For transfection of B78H1 cells, full-length human VCAM-1 cDNA was a kind gift from Dr. Roy Lobb of Biogen. The original construct [106] was subcloned into the pTRACER vector (Life Technologies Corp.). Transfection into B78H1 was done using the Lipofectamine transfection reagent (Life Technologies Corp). High receptor-expressing cells were sorted using a MoFlo flow cytometer (Beckman Coulter Inc.). Cells were grown at 37°C in a humidified atmosphere with 5% CO₂ and 95% air in RPMI 1640 (supplemented with 2 mM L-glutamine, 100 units/ml penicillin, 100 μ g/ml streptomycin, 10 mM HEPES, pH 7.4, and 10% heat-inactivated fetal bovine serum). Cells were counted using the Coulter Multisizer/Z2 analyzer (Beckman Coulter Inc.). For experiments, cells were suspended in warm RPMI (37°C) at 1×10^6 cells/ml and used immediately.

Kinetic analysis of binding and dissociation of VLA-4 specific ligand

Kinetic analysis of the binding and dissociation of the LDV-FITC probe was described previously [30,33]. Briefly, cells (1×10^6 cells/ml) were preincubated in warm RPMI under the appropriate conditions for 10–20 min at 37°C. Flow cytometric data were acquired for up to 1024 s at 37°C while the samples were stirred continuously at 300 rpm with a 5×2 mm magnetic stir bar (Bel-Art Products). Samples were analyzed for 30–120 s to establish a baseline. The fluorescent ligand was added and acquisition was re-established, creating a 5–10 s gap in the time course. For real-time affinity activation experiments, 4 nM LDV-FITC was added after establishing a baseline. Then, data were acquired for 2–3 minutes, and cells were treated with different GPCR ligands at saturating concentration (10 times or higher than K_d). In several experiments, cells were treated sequentially with two or more different compounds. Acquisition was re-established, and data were acquired continuously for up to 1024 s.

The concentration of the LDV-FITC probe used in activation experiments (4 nM) was below the dissociation constant (K_d) for its binding to resting VLA-4 (low affinity state, $K_d \sim 12$ nM), and above the K_d for physiologically activated VLA-4 (high affinity state, $K_d \sim 1$ –2 nM) [30]. Therefore, the transition from the low affinity to the high affinity receptor state led to increased binding of the probe (from ~25% to ~70 – 80% of receptor occupancy, as calculated based on the one site binding equation), which was detected as an increase in the mean fluorescence intensity. For kinetic dissociation measurements, cell samples were preincubated with the fluorescent probe (25 nM), treated with excess unlabeled LDV (2 μ M), and the dissociation of the fluorescent molecule was followed. The resulting data were converted to mean fluorescence intensity versus time using FCSQuery software developed by Dr. Bruce Edwards (University of New Mexico).

Cell aggregation assay

The cell suspension aggregation assay has been described previously [35,37]. Briefly, U937 cells were labeled with the green fluorescence PKH67GL dye, and B78H1/VCAM-1 transfectants were stained with the red fluorescence PKH26GL dye (Sigma-Aldrich). Labeled cells were washed, resuspended in RPMI and stored on ice until used in the assays. Control U937 cells were preincubated with the LDV molecule for blocking. Prior to data acquisition, cells were warmed to 37°C for 10 min separately and then mixed. During data acquisition, the samples were stirred with a 5×2 -mm magnetic stir bar (Bel-Art Products, Pequannock, NJ) at 300 rpm and kept at 37°C. The number of cell aggregates containing red and green co-fluorescent particles, and the number of singlets

were followed in real-time. The percentage of aggregates (Agg, %) was calculated as follows: $\text{Agg, \%} = (\text{number of aggregates} / (\text{number of aggregates} + \text{number of singlets})) \times 100$. Experiments were performed using a FACScan flow cytometer and Cell Quest software (Becton Dickinson, San Jose, CA). The real-time aggregation kinetic data were converted to Agg, % versus time using FCSQuery software developed by Dr. Bruce Edwards (University of New Mexico). Figures were prepared using Summit V4.3 software (Beckman Coulter Inc.).

Statistical analysis

Curve fits and statistics were performed using GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com. Each experiment was repeated two or three times. The experimental curves represent the mean of two or more independent runs. SEM was calculated using GraphPad Prism.

Abbreviations

CO: Carbon monoxide; CORM-2: Carbon monoxide-releasing molecule 2, tricarbonyldichlororuthenium (II) dimer; dbcAMP: N-6,2'-O-dibutyryladenine 3',5'-cyclic monophosphate; EPC: Endothelial progenitor cell; FITC: Fluorescein isothiocyanate; GC: Guanylyl cyclase; fMLFF: N-formyl-L-methionyl-L-leucyl-L-phenylalanyl-L-phenylalanine, formyl peptide; FPR: Formyl peptide receptor 1; GPCR: Guanine nucleotide binding protein coupled receptor; HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HO: Heme oxygenase; HSPC: Hematopoietic stem progenitor cell; LDV: 4-((N'-2-methylphenyl)ureido)-phenylacetyl-L-leucyl-L-aspartyl-L-valyl-L-prolyl-L-alanyl-L-alanyl-L-lysine; LDV-FITC: 4-((N'-2-methylphenyl)ureido)-phenylacetyl-L-leucyl-L-aspartyl-L-valyl-L-prolyl-L-alanyl-L-alanyl-L-lysine-FITC; LIBS: Ligand induced binding site; mAb: Monoclonal antibody; MCF: Mean channel fluorescence, equivalent of mean fluorescence intensity; NOS3 or eNOS: Endothelial nitric oxide synthase; SDF-1: Stromal cell-derived factor-1, CXCL12; VCAM-1: Vascular cell adhesion molecule 1, CD106; VLA-4: Very late antigen 4, CD49d/CD29, $\alpha 4 \beta 1$ integrin; VLA-5: Very late antigen 5, CD49e/CD29, $\alpha 5 \beta 1$ integrin.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AC designed the study and experiments, interpreted the experimental data, and wrote the manuscript; YS performed the experiments; LAS contributed to experimental design and manuscript preparation. All authors read and approved the final manuscript.

Acknowledgements

We thank Eric R. Prossnitz for providing cells and GPCR plasmids, Roy Lobb for providing VCAM-1 cDNA, Bruce S. Edwards for providing FCSQuery software, and George Tegos for fruitful scientific discussion. This work is supported by NIH grant R01HL081062 and U54MH084690 to LAS, and by Dedicated Health Research Funds of the University of New Mexico School of Medicine grant C-2297-RAC to AC.

Author details

¹Department of Pathology and University of New Mexico Cancer Center, Albuquerque, NM 87131, USA. ²University of New Mexico Center for Molecular Discovery, Albuquerque, NM 87131, USA. ³University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.

Received: 18 July 2014 Accepted: 21 October 2014

Published online: 31 October 2014

References

- Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH: Carbon monoxide: a putative neural messenger. *Science* 1993, **259**:381–384.

2. Otterbein LE, Bach FH, Alam J, Soares M, Tao LH, Wysk M, Davis RJ, Flavell RA, Choi AM: Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. *Nat Med* 2000, **6**:422–428.
3. Ryter SW, Alam J, Choi AM: Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. *Physiol Rev* 2006, **86**:583–650.
4. Ryter SW, Choi AM: Carbon monoxide: present and future indications for a medical gas. *Korean J Intern Med* 2013, **28**:123–140.
5. Rochette L, Cottin Y, Zeller M, Vergely C: Carbon monoxide: mechanisms of action and potential clinical implications. *Pharmacol Ther* 2013, **137**:133–152.
6. Hanafy KA, Oh J, Otterbein LE: Carbon monoxide and the brain: time to rethink the dogma. *Curr Pharm Des* 2013, **19**:2771–2775.
7. Snyder SH, Jaffrey SR, Zakhary R: Nitric oxide and carbon monoxide: parallel roles as neural messengers. *Brain Res Brain Res Rev* 1998, **26**:167–175.
8. Chigaev A, Smagley Y, Sklar LA: Nitric oxide/cGMP pathway signaling actively down-regulates alpha4beta1-integrin affinity: an unexpected mechanism for inducing cell de-adhesion. *BMC Immunol* 2011, **12**:28.
9. Chigaev A, Sklar LA: Aspects of VLA-4 and LFA-1 regulation that may contribute to rolling and firm adhesion. *Front Immunol* 2012, **3**:242.
10. Askari JA, Buckley PA, Mould AP, Humphries MJ: Linking integrin conformation to function. *J Cell Sci* 2009, **122**:165–170.
11. Ley K, Laudanna C, Cybulsky MI, Nourshargh S: Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nat Rev Immunol* 2007, **7**:678–689.
12. Gazitt Y: Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antineoplastic antibodies. *Leukemia* 2004, **18**:1–10.
13. Schneider JG, Amend SR, Weilbaecher KN: Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. *Bone* 2011, **48**:54–65.
14. Simon T, Pogu S, Tardif V, Rigaud K, Remy S, Piaggio E, Bach JM, Anegón I, Blancou P: Carbon monoxide-treated dendritic cells decrease beta1-integrin induction on CD8(+) T cells and protect from type 1 diabetes. *Eur J Immunol* 2013, **43**:209–218.
15. Dal Secco D, Freitas A, Abreu MA, Garlet TP, Rossi MA, Ferreira SH, Silva JS, Alves-Filho JC, Cunha FQ: Reduction of ICAM-1 expression by carbon monoxide via soluble guanylate cyclase activation accounts for modulation of neutrophil migration. *Naunyn Schmiedeberg Arch Pharmacol* 2010, **381**:483–493.
16. Urquhart P, Rosignoli G, Cooper D, Motterlini R, Perretti M: Carbon monoxide-releasing molecules modulate leukocyte-endothelial interactions under flow. *J Pharmacol Exp Ther* 2007, **321**:656–662.
17. Zhou JL, Wang QY, Du XR, Zhu XG, Ling YL, Liu QH: [Effect of exogenous carbon monoxide on sequestration of polymorphonuclear neutrophils in the lung following limb ischemia-reperfusion: an experimental study]. *Zhonghua Yi Xue Za Zhi* 2005, **85**:1987–1990.
18. Moncure M, Chen L, Childs EW, Smalley D, Udobi KF, Cheung LY: Heme-oxygenase-1 mRNA expression affects hemorrhagic shock-induced leukocyte adherence. *J Trauma* 2003, **55**:118–125.
19. Andersson JA, Egesten A, Cardell LO: Hemin, a heme oxygenase substrate analog, inhibits the cell surface expression of CD11b and CD66b on human neutrophils. *Allergy* 2002, **57**:718–722.
20. Kim HP, Ryter SW, Choi AM: CO as a cellular signaling molecule. *Annu Rev Pharmacol Toxicol* 2006, **46**:411–449.
21. Slebos DJ, Ryter SW, van der TM, Liu F, Guo F, Baty CJ, Karlsson JM, Watkins SC, Kim HP, Wang X, Lee JS, Postma DS, Kauffman HF, Choi AM: Mitochondrial localization and function of heme oxygenase-1 in cigarette smoke-induced cell death. *Am J Respir Cell Mol Biol* 2007, **36**:409–417.
22. Wu L, Wang R: Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. *Pharmacol Rev* 2005, **57**:585–630.
23. Motterlini R: Carbon monoxide-releasing molecules (CO-RMs): vasodilatory, anti-ischaemic and anti-inflammatory activities. *Biochem Soc Trans* 2007, **35**:1142–1146.
24. Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE, Green CJ: Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. *Circ Res* 2002, **90**:E17–E24.
25. Sun B, Sun H, Liu C, Shen J, Chen Z, Chen X: Role of CO-releasing molecules liberated CO in attenuating leukocytes sequestration and inflammatory responses in the lung of thermally injured mice. *J Surg Res* 2007, **139**:128–135.
26. Sun BW, Chen ZY, Chen X, Liu C: Attenuation of leukocytes sequestration by carbon monoxide-releasing molecules: liberated carbon monoxide in the liver of thermally injured mice. *J Burn Care Res* 2007, **28**:173–181.
27. Ma JL, Yang PY, Rui YC, Lu L, Kang H, Zhang J: Hemin modulates cytokine expressions in macrophage-derived foam cells via heme oxygenase-1 induction. *J Pharmacol Sci* 2007, **103**:261–266.
28. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz J, Ducke B, Feurer A, Furstner C: NO-independent stimulators of soluble guanylate cyclase. *Bioorg Med Chem Lett* 2001, **11**:781–784.
29. Schwede F, Maronde E, Genieser H, Jastorff B: Cyclic nucleotide analogs as biochemical tools and prospective drugs. *Pharmacol Ther* 2000, **87**:199–226.
30. Chigaev A, Blenc AM, Braaten JV, Kumaraswamy N, Kepley CL, Andrews RP, Oliver JM, Edwards BS, Prossnitz ER, Larson RS, Sklar LA: Real time analysis of the affinity regulation of alpha 4-integrin. The physiologically activated receptor is intermediate in affinity between resting and Mn(2+) or antibody activation. *J Biol Chem* 2001, **276**:48670–48678.
31. Chen LL, Whitty A, Lobb RR, Adams SP, Pepinsky RB: Multiple activation states of integrin alpha4beta1 detected through their different affinities for a small molecule ligand. *J Biol Chem* 1999, **274**:13167–13175.
32. Lin K, Ateeq HS, Hsiung SH, Chong LT, Zimmerman CN, Castro A, Lee WC, Hammond CE, Kalkunte S, Chen LL, Pepinsky RB, Leone DR, Sprague AG, Abraham WM, Gill A, Lobb RR, Adams SP: Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. *J Med Chem* 1999, **42**:920–934.
33. Chigaev A, Sklar LA: Overview: assays for studying integrin-dependent cell adhesion. *Methods Mol Biol* 2012, **757**:3–14.
34. Chigaev A, Waller A, Amit O, Sklar LA: Galphas-coupled receptor signaling actively down-regulates alpha4beta1-integrin affinity: a possible mechanism for cell de-adhesion. *BMC Immunol* 2008, **9**:26.
35. Chigaev A, Zwart G, Graves SW, Dwyer DC, Tsuji H, Foutz TD, Edwards BS, Prossnitz ER, Larson RS, Sklar LA: Alpha4beta1 integrin affinity changes govern cell adhesion. *J Biol Chem* 2003, **278**:38174–38182.
36. Newham P, Craig SE, Clark K, Mould AP, Humphries MJ: Analysis of ligand-induced and ligand-attenuated epitopes on the leukocyte integrin alpha4beta1: VCAM-1, mucosal addressin cell adhesion molecule-1, and fibronectin induce distinct conformational changes. *J Immunol* 1998, **160**:4508–4517.
37. Zwart G, Chigaev A, Foutz T, Larson RS, Posner R, Sklar LA: Relationship between Molecular and Cellular Dissociation Rates for VLA-4/VCAM-1 Interaction in the Absence of Shear Stress. *Biophys J* 2004, **86**:1243–1252.
38. Vines CM, Xue M, Maestas DC, Cimino DF, Prossnitz ER: Regulation of N-formyl peptide-mediated degranulation by receptor phosphorylation. *J Immunol* 2002, **169**:6760–6766.
39. Key TA, Foutz TD, Gurevich VV, Sklar LA, Prossnitz ER: N-formyl peptide receptor phosphorylation domains differentially regulate arrestin and agonist affinity. *J Biol Chem* 2003, **278**:4041–4047.
40. Prossnitz ER: Desensitization of N-formylpeptide receptor-mediated activation is dependent upon receptor phosphorylation. *J Biol Chem* 1997, **272**:15213–15219.
41. Chigaev A, Waller A, Amit O, Halip L, Bologna CG, Sklar LA: Real-time Analysis of Conformation-sensitive Antibody Binding Provides New Insights into Integrin Conformational Regulation. *J Biol Chem* 2009, **284**:14337–14346.
42. Sklar LA, Edwards BS, Graves SW, Nolan JP, Prossnitz ER: Flow cytometric analysis of ligand-receptor interactions and molecular assemblies. *Annu Rev Biophys Biomol Struct* 2002, **31**:97–119.
43. Edwards BS, Oprea T, Prossnitz ER, Sklar LA: Flow cytometry for high-throughput, high-content screening. *Curr Opin Chem Biol* 2004, **8**:392–398.
44. Megias J, Busserolles J, Alcaraz MJ: The carbon monoxide-releasing molecule CORM-2 inhibits the inflammatory response induced by cytokines in Caco-2 cells. *Br J Pharmacol* 2007, **150**:977–986.
45. Guillen MI, Megias J, Cleriques V, Gomar F, Alcaraz MJ: The CO-releasing molecule CORM-2 is a novel regulator of the inflammatory process in osteoarthritic chondrocytes. *Rheumatology (Oxford)* 2008, **47**:1323–1328.
46. Reiter CE, Alayash AI: Effects of carbon monoxide (CO) delivery by a CO donor or hemoglobin on vascular hypoxia inducible factor 1alpha and mitochondrial respiration. *FEBS Open Bio* 2012, **2**:113–118.
47. Sher EA, Shaklai M, Shaklai N: Carbon monoxide promotes respiratory hemoproteins iron reduction using peroxides as electron donors. *PLoS ONE* 2012, **7**:e33039.

48. Motterlini R, Sawle P, Hammad J, Bains S, Alberto R, Foresti R, Green CJ: **CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule.** *FASEB J* 2005, **19**:284–286.
49. Shokawa T, Yoshizumi M, Yamamoto H, Omura S, Toyofuku M, Shimizu Y, Imazu M, Kohno N: **Induction of heme oxygenase-1 inhibits monocyte chemoattractant protein-1 mRNA expression in U937 cells.** *J Pharmacol Sci* 2006, **100**:162–166.
50. Turpaev K, Bouton C, Drapier JC: **Nitric oxide-derived nitrosating species and gene expression in human monocytic cells.** *Biochemistry* 2004, **43**:10844–10850.
51. Miyazaki T, Kirino Y, Takeno M, Samukawa S, Hama M, Tanaka M, Yamaji S, Ueda A, Tomita N, Fujita H, Ishigatsubo Y: **Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1.** *Cancer Sci* 2010, **101**:1409–1416.
52. Nagai T, Kikuchi S, Ohmine K, Miyoshi T, Nakamura M, Kondo T, Furuyama K, Komatsu N, Ozawa K: **Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2.** *J Cell Biochem* 2008, **104**:680–691.
53. Chigaev A, Waller A, Zwart GJ, Buranda T, Sklar LA: **Regulation of cell adhesion by affinity and conformational unbending of alpha4beta1 integrin.** *J Immunol* 2007, **178**:6828–6839.
54. Njus BH, Chigaev A, Waller A, Wlodk D, Ostropovici-Halip L, Ursu O, Wang W, Oprea TI, Bologa CG, Sklar LA: **Conformational mAb as a tool for integrin ligand discovery.** *Assay Drug Dev Technol* 2009, **7**:507–515.
55. Chigaev A, Wu Y, Williams DB, Smagley Y, Sklar LA: **Discovery of very late antigen-4 (VLA-4, [alpha]4[beta]1 integrin) allosteric antagonists.** *J Biol Chem* 2011, **286**:5455–5463.
56. Chigaev A, Zwart GJ, Buranda T, Edwards BS, Prossnitz ER, Sklar LA: **Conformational regulation of alpha 4 beta 1-integrin affinity by reducing agents. "Inside-out" signaling is independent of and additive to reduction-regulated integrin activation.** *J Biol Chem* 2004, **279**:32435–32443.
57. Ryter SW, Morse D, Choi AM: **Carbon monoxide: to boldly go where NO has gone before.** *Sci STKE* 2004, **2004**:RE6.
58. Beavo JA, Brunton LL: **Cyclic nucleotide research – still expanding after half a century.** *Nat Rev Mol Cell Biol* 2002, **3**:710–718.
59. Dimitrov S, Shaikh F, Pruitt C, Green M, Wilson K, Beg N, Hong S: **Differential TNF production by monocyte subsets under physical stress: blunted mobilization of proinflammatory monocytes in prehypertensive individuals.** *Brain Behav Immun* 2013, **27**:101–108.
60. Dimitrov S, Benedict C, Heutling D, Westermann J, Born J, Lange T: **Cortisol and epinephrine control opposing circadian rhythms in T cell subsets.** *Blood* 2009, **113**:5134–5143.
61. Dimitrov S, Lange T, Born J: **Selective mobilization of cytotoxic leukocytes by epinephrine.** *J Immunol* 2010, **184**:503–511.
62. Benschop RJ, Schedlowski M, Wienecke H, Jacobs R, Schmidt RE: **Adrenergic control of natural killer cell circulation and adhesion.** *Brain Behav Immun* 1997, **11**:321–332.
63. Jetschmann JU, Benschop RJ, Jacobs R, Kemper A, Oberbeck R, Schmidt RE, Schedlowski M: **Expression and in-vivo modulation of alpha- and beta-adrenoceptors on human natural killer (CD16+) cells.** *J Neuroimmunol* 1997, **74**:159–164.
64. Schedlowski M, Hosch W, Oberbeck R, Benschop RJ, Jacobs R, Raab HR, Schmidt RE: **Catecholamines modulate human NK cell circulation and function via spleen-independent beta 2-adrenergic mechanisms.** *J Immunol* 1996, **156**:93–99.
65. Bruynzeel I, van der Raaij LM, Willemze R, Stoof TJ: **Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells.** *Arch Dermatol Res* 1997, **289**:189–193.
66. Benschop RJ, Rodriguez-Feuerhahn M, Schedlowski M: **Catecholamine-induced leukocytosis: early observations, current research, and future directions.** *Brain Behav Immun* 1996, **10**:77–91.
67. Benschop RJ, Nijkamp FP, Ballieux RE, Heijnen CJ: **The effects of beta-adrenoceptor stimulation on adhesion of human natural killer cells to cultured endothelium.** *Br J Pharmacol* 1994, **113**:1311–1316.
68. Alon R, Shulman Z: **Chemokine triggered integrin activation and actin remodeling events guiding lymphocyte migration across vascular barriers.** *Exp Cell Res* 2011, **317**:632–641.
69. Lapidot T, Petit I: **Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells.** *Exp Hematol* 2002, **30**:973–981.
70. Lapidot T, Dar A, Kollet O: **How do stem cells find their way home?** *Blood* 2005, **106**:1901–1910.
71. Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T: **Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.** *Blood* 2008, **111**:3439–3441.
72. Bonig H, Watts KL, Chang KH, Kiem HP, Papayannopoulou T: **Concurrent blockade of alpha4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization.** *Stem Cells* 2009, **27**:836–837.
73. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R: **The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.** *Blood* 2008, **111**:3893–3895.
74. Papayannopoulou T, Nakamoto B: **Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin.** *Proc Natl Acad Sci U S A* 1993, **90**:9374–9378.
75. Ramirez P, Rettig MP, Uy GL, Deych E, Holt MS, Ritchey JK, DiPersio JF: **BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells.** *Blood* 2009, **114**:1340–1343.
76. Dar A, Schajnovitz A, Lapid K, Kalinkovich A, Itkin T, Ludin A, Kao WM, Battista M, Tesio M, Kollet O, Cohen NN, Margalit R, Buss EC, Baleux F, Oishi S, Fujii N, Larochelle A, Dunbar CE, Broxmeyer HE, Frenette PS, Lapidot T: **Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.** *Leukemia* 2011, **25**:1286–1296.
77. Lapid K, Itkin T, D'Uva G, Ovadya Y, Ludin A, Caglio G, Kalinkovich A, Golan K, Porat Z, Zollo M, Lapidot T: **GSK3beta regulates physiological migration of stem/progenitor cells via cytoskeletal rearrangement.** *J Clin Invest* 2013, **123**:1705–1717.
78. Kollet O, Shvitiel S, Chen YQ, Suriawinata J, Thung SN, Dabeva MD, Kahn J, Spiegel A, Dar A, Samira S, Goichberg P, Kalinkovich A, Arenzana-Seisdedos F, Nagler A, Hardan I, Revel M, Shafritz DA, Lapidot T: **HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver.** *J Clin Invest* 2003, **112**:160–169.
79. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S: **Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells.** *Nat Med* 2003, **9**:1370–1376.
80. Holmes K, Roberts OL, Thomas AM, Cross MJ: **Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.** *Cell Signal* 2007, **19**:2003–2012.
81. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, Rafii S: **Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1.** *Ann N Y Acad Sci* 2001, **938**:36–45.
82. Aicher A, Heeschen C, Dimmeler S: **The role of NOS3 in stem cell mobilization.** *Trends Mol Med* 2004, **10**:421–425.
83. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM: **Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation.** *Nature* 1999, **399**:601–605.
84. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC: **Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.** *Nature* 1999, **399**:597–601.
85. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC: **Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.** *J Clin Invest* 1997, **100**:3131–3139.
86. Ozuyaman B, Ebner P, Niesler U, Ziemann J, Kleinbongard P, Jax T, Godecke A, Kelm M, Kalka C: **Nitric oxide differentially regulates proliferation and mobilization of endothelial progenitor cells but not of hematopoietic stem cells.** *Thromb Haemost* 2005, **94**:770–772.
87. Mebius RE, Kraal G: **Structure and function of the spleen.** *Nat Rev Immunol* 2005, **5**:606–616.
88. Kovtunovich G, Eckhaus MA, Ghosh MC, Ollivierre-Wilson H, Rouault TA: **Dysfunction of the heme recycling system in heme oxygenase 1-deficient mice: effects on macrophage viability and tissue iron distribution.** *Blood* 2010, **116**:6054–6062.
89. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ: **Identification of splenic reservoir monocytes and their deployment to inflammatory sites.** *Science* 2009, **325**:612–616.
90. Gaillard CA, Schiffelers RM: **Red blood cell: barometer of cardiovascular health?** *Cardiovasc Res* 2013, **98**:3–4.
91. Mo RR, Eisenbraun JK, Sonstein J, Craig RA, Curtis JL, Stoolman LM, Chen J, Yung RL: **CD49d overexpression and T cell autoimmunity.** *J Immunol* 2003, **171**:745–753.

92. Jaeschke H: **Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning.** *Am J Physiol Gastrointest Liver Physiol* 2003, **284**:G15–G26.
93. Yilmaz G, Granger DN: **Cell adhesion molecules and ischemic stroke.** *Neurol Res* 2008, **30**:783–793.
94. Duarte S, Shen XD, Fondevila C, Busuttil RW, Coito AJ: **Fibronectin- α 4 β 1 interactions in hepatic cold ischemia and reperfusion injury: regulation of MMP-9 and MT1-MMP via the p38 MAPK pathway.** *Am J Transplant* 2012, **12**:2689–2699.
95. Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN, Csizmadia E, Tyagi S, Akamatsu Y, Flavell RJ, Billiar TR, Tzeng E, Bach FH, Choi AM, Soares MP: **Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury.** *Nat Med* 2003, **9**:183–190.
96. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM: **Hemolysis and free hemoglobin revisited: exploring hemoglobin and heme scavengers as a novel class of therapeutic proteins.** *Blood* 2013, **121**:1276–1284.
97. Larsen R, Gozzelino R, Jeney V, Tokaji L, Bozza FA, Japiassu AM, Bonaparte D, Cavalcante MM, Chora A, Ferreira A, Marguti I, Cardoso S, Sepulveda N, Smith A, Soares MP: **A central role for free heme in the pathogenesis of severe sepsis.** *Sci Transl Med* 2010, **2**:51ra71.
98. Wang QQ, Li H, Oliver T, Glogauer M, Guo J, He YW: **Integrin beta 1 regulates phagosome maturation in macrophages through Rac expression.** *J Immunol* 2008, **180**:2419–2428.
99. Jia W, Li H, He YW: **The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment.** *Blood* 2005, **106**:3854–3859.
100. Li Y, Cao C, Jia W, Yu L, Mo M, Wang Q, Huang Y, Lim JM, Ishihara M, Wells L, Azadi P, Robinson H, He YW, Zhang L, Mariuzza RA: **Structure of the F-spondin domain of mindin, an integrin ligand and pattern recognition molecule.** *EMBO J* 2009, **28**:286–297.
101. Humphries JD, Byron A, Humphries MJ: **Integrin ligands at a glance.** *J Cell Sci* 2006, **119**:3901–3903.
102. He YW, Li H, Zhang J, Hsu CL, Lin E, Zhang N, Guo J, Forbush KA, Bevan MJ: **The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens.** *Nat Immunol* 2004, **5**:88–97.
103. Bhakdi S, Bayley H, Valeva A, Walev I, Walker B, Kehoe M, Palmer M: **Staphylococcal alpha-toxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins.** *Arch Microbiol* 1996, **165**:73–79.
104. Bebien M, Hensler ME, Davanture S, Hsu LC, Karin M, Park JM, Alexopoulou L, Liu GY, Nizet V, Lawrence T: **The pore-forming toxin beta hemolysin/cytolysin triggers p38 MAPK-dependent IL-10 production in macrophages and inhibits innate immunity.** *PLoS Pathog* 2012, **8**:e1002812.
105. Kew RR, Peng T, DiMartino SJ, Madhavan D, Weinman SJ, Cheng D, Prossnitz ER: **Undifferentiated U937 cells transfected with chemoattractant receptors: a model system to investigate chemotactic mechanisms and receptor structure/function relationships.** *J Leukoc Biol* 1997, **61**:329–337.
106. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G, Lobb R: **Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes.** *Cell* 1989, **59**:1203–1211.

doi:10.1186/s12865-014-0052-1

Cite this article as: Chigaev et al.: Carbon monoxide down-regulates α 4 β 1 integrin-specific ligand binding and cell adhesion: a possible mechanism for cell mobilization. *BMC Immunology* 2014 **15**:52.

Submit your next manuscript to BioMed Central and take full advantage of:

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at
www.biomedcentral.com/submit